H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Niagen Bioscience today and set a price target of $12.00. The company’s shares closed yesterday at $7.26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Vanda. According to TipRanks, Selvaraju has an average return of 23.6% and a 57.63% success rate on recommended stocks.
In addition to H.C. Wainwright, Niagen Bioscience also received a Buy from TR | OpenAI – 4o’s Dex Genotek in a report issued on October 1. However, on October 2, TR | OpenAI – 4o downgraded Niagen Bioscience (NASDAQ: NAGE) to a Hold.
Based on Niagen Bioscience’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $31.12 million and a net profit of $3.61 million. In comparison, last year the company earned a revenue of $22.74 million and had a GAAP net loss of $15 thousand
Read More on NAGE:
Disclaimer & DisclosureReport an Issue
- Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling
- Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
- Niagen Bioscience raises FY25 revenue view to up 25%-30% from up 22%-27%
- Niagen Bioscience’s Niagen IV, injections now available at iCRYO clinics
- Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/PayPal%20Holdings%20Inc%20HQ%20photo-by%20bennymarty%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)